

# **Exhibit F**

Date of entry 09/01/2021

Urioste (CFTC). [REDACTED]  
[REDACTED]  
[REDACTED]

11/11/2016

[REDACTED]

[REDACTED]

\_\_\_\_\_

\_\_\_\_\_

Date drafted 08/05/2021

3501-001  
Becker, Scott  
Page 1 of 12

318B-NY-3416770

(U) Interview of Scott Becker on

Continuation of FD-302 of 08/03/2021 , On 08/03/2021 , Page 4 of 12

In early 2020, ACM had a large short position in TESLA that had not performed well, and by February 2020, the firm was down roughly 70% year-to-date, largely as a result of the TESLA position. ACM's gross exposure and leverage had grown extremely high because of this poor performance, and between February and April 2020, ACM's prime brokers were calling more frequently for updates.

BECKER asked HALLIGAN what he should tell the banks about ACM's gross exposure. In response, HALLIGAN created a monthly report that calculated ACM's year-to-date average gross exposure, a number that significantly understated the firm's true gross exposure at the time. HALLIGAN told BECKER to provide that misleading figure to the banks in response to their questions.

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[illegible]

[REDACTED]

[REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]